NCT07572370 Evaluating the De-Escalation of Surveillance for Patients Who Have Undergone Curative Treatment for Breast Cancer
| NCT ID | NCT07572370 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Royal College of Surgeons, Ireland |
| Condition | Breast Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 560 participants |
| Start Date | 2025-12-11 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 560 participants in total. It began in 2025-12-11 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Patients who were diagnosed with breast cancer and have finished their treatment will be given the opportunity to be part of this study. These patients will have been attending surveillance at the Breast Centre in Beaumont Hospital, Ireland for 2 years prior. These patients, who are doing well after breast cancer treatment, will be given the opportunity to enrol in this study, potentially being discharged from in person surveillance after 2 years, while still attending for their annual mammogram. Investigators intend to find out if a simpler follow-up plan could work just as safely, while also improving the patients quality of life.
Eligibility Criteria
Inclusion Criteria: * Female participants aged 18 years or older * Prior diagnosis of primary breast cancer treated with curative intent * Currently under cancer surveillance and at the 24-month follow-up timepoint * No clinical or radiological evidence of disease recurrence or metastasis at the time of recruitment (e.g., no palpable mass, skin or nipple changes, or suspicious findings on imaging) * Able to read, write, and speak English sufficiently to complete the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire (paper-based or via telephone) * Resident in the Republic of Ireland with a fixed address and intention to continue follow-up within the Irish healthcare system Exclusion Criteria: * Evidence of breast cancer recurrence or metastatic disease at the time of recruitment * Inability to provide informed consent * Inability to complete study questionnaires (e.g., due to language barriers or cognitive impairment) * Not resident in the Republic of Ireland or not intending to remain in follow-up within the Irish healthcare system
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07572370 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07572370 currently recruiting?
Yes, NCT07572370 is actively recruiting participants. Contact the research team at eforde@rcsi.com for enrollment information.
Where is the NCT07572370 trial being conducted?
This trial is being conducted at Dublin, Ireland.
Who is sponsoring the NCT07572370 clinical trial?
NCT07572370 is sponsored by Royal College of Surgeons, Ireland. The trial plans to enroll 560 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.